Benefits of Taxotere®
 How is Taxotere® Given
 Taxotere® Side Effects
 What Is/Causes Cancer?
 What Is Cancer Staging?
 TNM Staging
 Cancer Facts
 FAQ Chemotherapy
 Managing Side Effects
 Educational Materials
 Questions to Ask
 Clinical Trials
 Useful Links
Taxotere logo
US Resident
+ Font size - | Print Print | Email to a Friend Email to a Friend | Prescribing Information & Boxed Warning
Home Taxotere® Treatment About Cancer Understanding Chemotherapy Helpful Resources Healthcare Professionals
 
Benefits of Taxotere®
How is Taxotere® Given
Taxotere® Side Effects
What Is/Causes Cancer?
What IS Cancer Staging?
TMN Staging
Cancer Facts
FAQ Chemotherapy
Managing Side Effects
Education Materials
Questions to Ask
Clinical Trials
Useful Links
 
table bottom
 Home 
Taxotere® Treatment
About Cancer
Understanding Chemotherapy
Helpful Resources
Healthcare Professionals
Skip Navigation Links > Home > Sitemap

Site Map

Breast Cancer

Benefits of Taxotere®

About Breast Cancer

Risk Factors

Screening

Treatment Options

Questions to Ask

Useful Links

Lung Cancer

Benefits of Taxotere®

About Lung Cancer

Risk Factors

Screening

Treatment Options

Questions to Ask

Useful Links

Prostate Cancer

Benefits of Taxotere®

About Prostate Cancer

Risk Factors

Screening

Treatment Options

Questions to Ask

Useful Links

Gastric/GE Junction Cancer

Benefits of Taxotere®

About Gastric Cancer

Risk Factors

Screening

Treatment Options

Questions to Ask

Useful Links

Head & Neck Cancer

Benefits of Taxotere®

About Head and Neck Cancer

Risk Factors

Screening

Treatment Options

Questions to Ask

Useful Links

Taxotere® Treatment

Benefits of Taxotere®

How is Taxotere® Given

Taxotere® Side Effects

About Cancer

What Is/Causes Cancer?

What Is Cancer Staging?

TNM Staging

Cancer Facts

Understanding Chemotherapy

FAQ Chemotherapy

FAQ Side Effects

Helpful Resources

Managing Side Effects

Educational Materials

Questions to Ask

Clinical Trials

Useful Links

Helpful Resources

Chemotherapy can be managed through education preparation. To be better equipped to help yourself and your family, visit the Helpful Resource section.

learn more
Helpful Resources
Prescribing Information | Site Map | Terms of Use | Privacy Policy | Contact Us
Sanofi-Aventis
© 2002- 2008 sanofi-aventis U.S. LLC. All rights reserved.
Legal Disclaimer Information and Privacy Policy
Questions or Comments? Click here to contact us.
This site intended for use by U.S. residents only.
US.DOC.06.04.162  Last update:  May 2007
IMPORTANT SAFETY INFORMATION

WARNING: Taxotere® treatment can cause serious, physically limiting, and potentially life-threatening side effects, such as infection, low blood-cell counts, allergic reaction, and retention of excess fluid (edema).

Taxotere® should not be given to patients with low white–blood-cell counts, abnormal liver function, or a history of allergic reactions to Taxotere® or any of the ingredients in Taxotere®.

Before each Taxotere® treatment, all patients treated with Taxotere® must receive another medicine called dexamethasone. This drug can help reduce the risk of fluid retention (edema) and allergic reactions.

Taxotere® should be administered only under the supervision of a qualified physician experienced in the use of anticancer treatments. Appropriate management of complications is possible only when adequate diagnostic and treatment facilities are readily available.

Treatment-related acute myeloid leukemia (AML) or myelodysplasia has occurred in patients given anthracyclines and/or cyclophosphamide, including use with Taxotere® in adjuvant therapy for breast cancer.

The most common severe side effects are low white–blood-cell count, anemia, fatigue, diarrhea, and mouth and throat irritation. Low white–blood-cell count can lead to life-threatening infections. The earliest sign of infection may be fever, so tell your doctor right away if you have a fever.

Other common side effects from Taxotere® include nausea, vomiting, hair loss, rash, infusion-site reactions, odd sensations (such as numbness, tingling, or burning) or weakness in the hands and feet, nail changes, muscle and/or bone pain, or excessive tearing.

Because of the potential risk of fetal harm, pregnant women should not receive Taxotere®. Women of childbearing potential should avoid becoming pregnant during treatment with Taxotere®.

Before receiving Taxotere®, tell your doctor if

  • You have any allergies
  • You are taking any other medicines — including nonprescription (over-the-counter) drugs, vitamins, and dietary or herbal supplements

When taking Taxotere®, contact your doctor if

  • You have symptoms of an allergic reaction (warm sensation, tightness in your chest, itching/hives, or shortness of breath)
  • You experience any other side effects

Please see adjacent page for patient information leaflet for detailed information about these side effects, and talk to your doctor about any questions you may have.

Taxotere Indications

Breast Cancer
TAXOTERE® is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy
TAXOTERE® in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer

Non-Small Cell Lung Cancer
TAXOTERE®, as a single agent, is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy
TAXOTERE® in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic NSCLC who have not previously received chemotherapy for this condition.

Prostate Cancer
TAXOTERE® in combination with prednisone is indicated for the treatment of patients with androgen independent (hormone refractory) metastatic prostate cancer.

Gastric Cancer
TAXOTERE® in combination with cisplatin and flouroucil is indicated for the treatment of patients with advanced gastric adenocercinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease.

Head and neck Cancer
TAXOTERE® in combination with cisplatin and flourouracil is indicated for the induction treatment of patients with locally advanced squamous cell cercinoma of the head and neck (SCCHN).